Jassem E, Gan J, Cynowska B
Kliniki Chorób Płuc i Gruźlicy AM w Gdańsku.
Pneumonol Alergol Pol. 1995;63(7-8):415-20.
The aim of this study was to assess a prognostic value of serum specific enolase (NSE) measurement in lung cancer patients. Total number of 105 patients entered the study, including 36 patients with small cell carcinoma and 69 patients with non small cell carcinoma (21-squamous cell carcinoma, 32-adenocarcinoma, 14-large cell carcinoma). Elevated NSE level was observed in 47 (44.8%) patients: in 75% of SCLC patients and 29% of NSCLC patients (p < 0.001). Median survival in NSCLC patients with elevated NSE levels was 27 weeks and in those with normal values-59 weeks. The probability of one year survival in both groups was 22% and 45% respectively (p = 0.27). Median survival in SCLC patients with elevated NSE test was 30 weeks and in those normal levels-61 weeks and the probability of one years survival in both groups was 26% and 62%, respectively (p = 0.34).
本研究的目的是评估血清特异性烯醇化酶（NSE）检测在肺癌患者中的预后价值。共有105例患者进入本研究，其中36例为小细胞癌患者，69例为非小细胞癌患者（21例鳞状细胞癌、32例腺癌、14例大细胞癌）。47例（44.8%）患者的NSE水平升高：小细胞肺癌患者中75%升高，非小细胞肺癌患者中29%升高（p<0.001）。NSE水平升高的非小细胞肺癌患者的中位生存期为27周，NSE水平正常的患者为59周。两组患者的一年生存率分别为22%和45%（p=0.27）。NSE检测水平升高的小细胞肺癌患者的中位生存期为30周，检测水平正常的患者为61周，两组患者的一年生存率分别为26%和62%（p=0.34）。
